These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 1965108)
1. Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus type 1 infection in immunosuppressed mice. Ijichi K; Ashida N; Machida H Antimicrob Agents Chemother; 1990 Dec; 34(12):2431-3. PubMed ID: 1965108 [TBL] [Abstract][Full Text] [Related]
2. In vitro and in vivo antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) and related compounds. Machida H; Sakata S Antiviral Res; 1984 Jun; 4(3):135-41. PubMed ID: 6089657 [TBL] [Abstract][Full Text] [Related]
3. Topical treatment with BV-araU of immunosuppressed and immunocompetent shaved mice cutaneously infected with herpes simplex virus type 1. Ijichi K; Ashida N; Varia S; Machida H Antiviral Res; 1993 May; 21(1):47-57. PubMed ID: 8391248 [TBL] [Abstract][Full Text] [Related]
4. Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (brovavir) on experimental infections in mice with herpes simplex virus type 1 strains of different degrees of virulence. Machida H; Takezawa J Antimicrob Agents Chemother; 1990 May; 34(5):691-6. PubMed ID: 2163240 [TBL] [Abstract][Full Text] [Related]
5. Comparison of antiviral efficacies of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (brovavir) and acyclovir against herpes simplex virus type 1 infections in mice. Machida H; Ikeda T; Ashida N Antiviral Res; 1990 Aug; 14(2):99-107. PubMed ID: 2177319 [TBL] [Abstract][Full Text] [Related]
6. Effects of various nucleosides on antiviral activity and metabolism of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against herpes simplex virus types 1 and 2. Suzutani T; Machida H; Sakuma T; Azuma M Antimicrob Agents Chemother; 1988 Oct; 32(10):1547-51. PubMed ID: 2847634 [TBL] [Abstract][Full Text] [Related]
7. Efficacy of oral treatment with BV-araU against cutaneous infection with herpes simplex type 1 in shaved mice. Machida H; Ijichi K; Takezawa J Antiviral Res; 1992 Feb; 17(2):133-43. PubMed ID: 1554238 [TBL] [Abstract][Full Text] [Related]
8. Metabolic fate of [3H]1-beta-D-arabinofuranosyl-5-[(E)-2-bromovinyl]uracil in herpes simplex virus type 1-infected cells. Ashida N; Sakata S; Machida H Microbiol Immunol; 1997; 41(12):957-64. PubMed ID: 9492181 [TBL] [Abstract][Full Text] [Related]
9. Comparison of two bromovinyl nucleoside analogs, 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil and E-5-(2-bromovinyl)-2'-deoxyuridine, with acyclovir in inhibition of Epstein-Barr virus replication. Lin JC; Machida H Antimicrob Agents Chemother; 1988 Jul; 32(7):1068-72. PubMed ID: 2847639 [TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo anti-herpes viral activities and biological properties of CV-araU. Ashida N; Sakata S; Kano F; Nishitani M; Watanabe Y; Machida H Antiviral Res; 1994 Dec; 25(3-4):179-84. PubMed ID: 7710267 [TBL] [Abstract][Full Text] [Related]
11. Mechanism of selective inhibition of varicella zoster virus replication by 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Yokota T; Konno K; Mori S; Shigeta S; Kumagai M; Watanabe Y; Machida H Mol Pharmacol; 1989 Aug; 36(2):312-6. PubMed ID: 2549386 [TBL] [Abstract][Full Text] [Related]
12. Antiviral activity of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil against thymidine kinase negative strains of varicella-zoster virus. Kawai H; Yoshida I; Suzutani T Microbiol Immunol; 1993; 37(11):877-82. PubMed ID: 8295566 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of 5-vinyl-1-beta-D-arabinofuranosyluracil (VaraU) against herpes simplex virus type 2 strains in cell cultures and against experimental herpes encephalitis in mice: comparison with acyclovir and foscarnet. Reefschläger J; Wutzler P; Thiel KD; Herrmann G Pharm Res; 1987 Jun; 4(3):200-6. PubMed ID: 2855541 [TBL] [Abstract][Full Text] [Related]
14. Different antiviral potencies of BV-araU and related nucleoside analogues against herpes simplex virus type 1 in human cell lines and Vero cells. Machida H; Nishitani M; Suzutani T; Hayashi K Microbiol Immunol; 1991; 35(11):963-73. PubMed ID: 1663576 [TBL] [Abstract][Full Text] [Related]
15. Treatment of experimental herpes simplex virus type 1 encephalitis in mice with (E)-5-(2-bromovinyl)- and 5-vinyl-1-beta-D-arabinofuranosyluracil: comparison with bromovinyl-deoxyuridine and acyclovir. Reefschläger J; Wutzler P; Thiel KD; Herrmann G Antiviral Res; 1986 Mar; 6(2):83-93. PubMed ID: 3010858 [TBL] [Abstract][Full Text] [Related]
16. Effect of BV-araU and acyclovir on varicella-zoster virus replication with various length and timing of drug exposure. Machida H; Nishitani M; Ashida N Microbiol Immunol; 1994; 38(2):109-15. PubMed ID: 8041297 [TBL] [Abstract][Full Text] [Related]
17. Strains of varicella-zoster virus resistant to 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil. Sakuma T Antimicrob Agents Chemother; 1984 Jun; 25(6):742-6. PubMed ID: 6331298 [TBL] [Abstract][Full Text] [Related]
18. Oral bioavailability and anti-simian varicella virus efficacy of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) in monkeys. Soike K; Huang JL; Tu JI; Stouffer B; Mitroka JG; Swerdel M; Olsen S; Bonner DP; Tuomari AV; Field AK J Infect Dis; 1992 Apr; 165(4):732-6. PubMed ID: 1313071 [TBL] [Abstract][Full Text] [Related]
19. Antiviral potencies of BV-araU and related nucleoside analogues against varicella-zoster virus in different cell lines. Machida H; Ijichi K; Ohta A; Honda M; Niimura M Microbiol Immunol; 1990; 34(11):959-65. PubMed ID: 1965323 [TBL] [Abstract][Full Text] [Related]
20. Analysis of toxic and mutagenic activities of antiherpesvirus nucleosides against HeLa cells and herpes simplex virus type 1. Suzutani T; Machida H Mutat Res; 1992 May; 267(1):125-31. PubMed ID: 1373847 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]